Congress moves to protect biomaterial manufacturers from lengthy and frivolous lawsuits
This article was originally published in Clinica
The key US House Commerce Committee is expected to approve legislation this week that would protect biomaterial manufacturers from being included in frivolous product liability lawsuits involving allegedly faulty implanted medical devices.
You may also be interested in...
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.